Path: `/mechanisms/pp2a-tau-phosphatase-pathway` Tags: `section:mechanisms`, `kind:pathway`, `topic:tauopathy`, `topic:phosphatase`, `topic:signal-transduction`
Path: `/mechanisms/pp2a-tau-phosphatase-pathway` Tags: `section:mechanisms`, `kind:pathway`, `topic:tauopathy`, `topic:phosphatase`, `topic:signal-transduction`
Protein Phosphatase 2A (PP2A) represents one of the most important serine/threonine phosphatases in eukaryotic cells, accounting for the majority of tau dephosphorylation activity in the brain[@liu2005]. This enzyme plays a critical role in maintaining the physiological balance between tau phosphorylation and dephosphorylation, a process that becomes severely dysregulated in Alzheimer's disease (AD) and related tauopathies. The PP2A holoenzyme is a heterotrimeric complex comprising a catalytic subunit (PP2A-C), a structural subunit (PP2A-A), and one of multiple regulatory subunits (PP2A-B) that together determine substrate specificity, subcellular localization, and catalytic activity[@xing2006]. In neurodegenerative diseases, particularly Alzheimer's disease and progressive supranuclear palsy (PSP), PP2A activity is significantly reduced, leading to hyperphosphorylation of the microtubule-associated protein tau and subsequent neurofibrillary tangle formation[@gong2006]. This dysregulation of the PP2A-tau axis has become increasingly recognized as a central mechanism in tauopathy pathogenesis, making it an attractive target for therapeutic intervention. The balance between protein kinases and phosphatases like PP2A determines the phosphorylation state of tau at multiple serine and threonine residues, and disruption of this balance toward hyperphosphorylation contributes to tau aggregation and neurotoxicity[@braithwaite2012].
The PP2A tau phosphatase pathway encompasses not only the direct dephosphorylation of tau by the PP2A holoenzyme but also includes the intricate regulatory networks that control PP2A activity itself. These regulatory mechanisms include post-translational modifications of PP2A subunits, interaction with endogenous inhibitors, and association with various regulatory proteins that modulate holoenzyme assembly and function. Understanding these regulatory pathways is essential for comprehending how PP2A activity becomes reduced in tauopathies and how therapeutic strategies might restore proper tau dephosphorylation. Furthermore, the PP2A pathway interacts with multiple signaling cascades that influence tau phosphorylation, creating a complex network of regulation that extends beyond simple enzyme-substrate relationships[@sontag2014]. The significance of PP2A in tau biology is underscored by observations that genetic or pharmacological inhibition of PP2A leads to tau hyperphosphorylation in cellular and animal models, while restoration of PP2A activity can mitigate tau pathology in experimental systems.
The PP2A holoenzyme represents a sophisticated molecular machine composed of three distinct subunits that assemble to form a functional phosphatase complex. The catalytic subunit (PPP2CA or PP2A-C) contains the active site responsible for removing phosphate groups from phosphorylated serine and threonine residues on target proteins including tau[@shi2001]. The C-terminal domain of PP2A-C harbors a metal-binding site that coordinates two manganese ions essential for catalytic activity, and this region undergoes extensive post-translational modifications including methylation at a conserved C-terminal leucine residue and phosphorylation at tyrosine and threonine residues that regulate enzyme function[@xing2000]. The catalytic core shares structural homology with other members of the phosphoprotein phosphatase (PPP) family, including PP1, PP2B, and PP2C, but PP2A possesses unique regulatory features that enable its diverse substrate specificity and tissue-specific functions.
The structural subunit (PPP2R2A or PP2A-A, also known as PR65) forms a scaffold consisting of 15 tandem repeat sequences arranged in an armadillo-like repeat structure that connects the catalytic and regulatory subunits[@groves1999]. This scaffolding subunit adopts a horseshoe-shaped conformation that provides multiple interaction surfaces for binding both the catalytic subunit and regulatory B-subunits simultaneously. The structural subunit is essential for maintaining the proper conformation of the holoenzyme and for facilitating the dynamic exchange of regulatory subunits that determine PP2A function in different cellular contexts. Mutations or alterations in the structural subunit can disrupt holoenzyme assembly and contribute to dysregulated phosphatase activity in disease states.
The regulatory subunit (PPP2R2A and related family members collectively termed B-subunits or PP2A-B) represents the most diverse component of the PP2A holoenzyme, with multiple isoforms encoded by distinct genes and alternatively spliced variants providing tremendous functional diversity[@janssens2008]. These regulatory subunits determine substrate specificity by directly binding to target proteins and positioning them for dephosphorylation by the catalytic subunit. The B-subunits also modulate PP2A localization within different cellular compartments, including the cytoplasm, nucleus, and membrane structures. In the context of tau dephosphorylation, specific regulatory subunits such as the Bα (PPP2R2A) and Bβ (PPP2R2B) isoforms are particularly important for targeting PP2A to tau in the brain, and alterations in the expression or function of these regulatory subunits contribute to reduced tau dephosphorylation in AD[@xu2013].
The assembly of the PP2A holoenzyme is regulated by several additional proteins that facilitate proper subunit pairing and post-translational modification. The PP2A methyltransferase (PPMT or PRMT5) catalyzes the C-terminal methylation of the catalytic subunit, which is required for high-affinity binding of most regulatory subunits[@stanevich2011]. Conversely, the PP2A methylesterase (PME-1 or PPME1) removes this methyl group, promoting holoenzyme disassembly and providing a mechanism for dynamic regulation of PP2A composition. The interaction between these enzymes and the PP2A holoenzyme creates a methylation-demethylation cycle that controls the availability of catalytically active phosphatase complexes for specific cellular functions.
Tau is a microtubule-associated protein expressed primarily in neurons, where it plays essential roles in promoting microtubule assembly, maintaining cytoskeletal stability, and regulating axonal transport[@ballatore2007]. The tau protein contains over 80 potential serine and threonine phosphorylation sites, making it one of the most heavily phosphorylated proteins in the nervous system. Under physiological conditions, tau phosphorylation is dynamically regulated by the coordinated action of protein kinases and phosphatases, with the phosphorylation state reflecting the balance between these opposing enzymatic activities. In the adult brain, tau is typically phosphorylated at low to moderate levels, with specific phosphorylation patterns that modulate its microtubule-binding affinity and functional properties.
The phosphorylation of tau at disease-associated sites is mediated by several serine/threonine kinases, including glycogen synthase kinase-3β (GSK-3β), cyclin-dependent kinase 5 (CDK5), and several members of the mitogen-activated protein kinase (MAPK) family[@himmelstein2012]. GSK-3β is particularly important for tau phosphorylation at many sites implicated in AD pathogenesis, including Ser9, Ser396, and Thr181. CDK5, in combination with its regulatory partner p35 or p39, phosphorylates tau atThr181, Ser202, and Ser235, among other sites. These kinases can act synergistically to promote hyperphosphorylation of tau, and their activities are subject to regulation by multiple signaling pathways that become dysregulated in AD.
The dephosphorylation of tau is primarily mediated by PP2A, which accounts for approximately 70% of the total tau dephosphorylation activity in brain tissue[@liu2008]. PP2A efficiently dephosphorylates tau at most disease-relevant phosphorylation sites, including those targeted by GSK-3β and CDK5. The specificity of PP2A for tau dephosphorylation is determined by the composition of the PP2A holoenzyme, with specific regulatory B-subunits facilitating the interaction between PP2A and tau. The dephosphorylation of tau by PP2A restores its microtubule-binding capacity and promotes microtubule assembly, thereby counteracting the pathogenic effects of tau hyperphosphorylation. Importantly, PP2A can dephosphorylate tau that has been phosphorylated at multiple sites, suggesting it can processively remove phosphate groups from hyperphosphorylated tau molecules.
The physiological regulation of tau phosphorylation extends beyond simple kinase-phosphatase balance to include additional layers of control. Tau itself contains binding domains for PP2A that facilitate its recruitment to the phosphatase complex, and the phosphorylation state of tau can influence its interaction with PP2A[@vintem2009]. Additionally, several proteins that regulate PP2A activity, including the endogenous inhibitor proteins CIP2A (cancerous inhibitor of PP2A) and SET (also known as I2PP2A), can modulate tau dephosphorylation by controlling PP2A availability. The dysregulation of these regulatory mechanisms contributes to the reduced PP2A activity and consequent tau hyperphosphorylation observed in AD brain tissue.
The activity of PP2A is subject to extensive regulation at multiple levels, including post-translational modifications of the catalytic subunit, interaction with endogenous inhibitor proteins, and control of holoenzyme assembly through methylation dynamics. These regulatory mechanisms provide tight control over PP2A function in response to cellular signals and ensure proper spatial and temporal regulation of phosphatase activity. In the context of tau dephosphorylation, dysregulation of these control mechanisms contributes to reduced PP2A activity and the development of tau pathology in AD[@sontag1995].
The methylation of PP2A-C at the C-terminal Leu309 residue by the methyltransferase PRMT5 is essential for the assembly of most PP2A holoenzymes containing regulatory B-subunits[@kalhor2001]. This methylation creates a hydrophobic surface that facilitates high-affinity binding between the catalytic and regulatory subunits. The methylation status of PP2A is dynamically regulated by the opposing activities of PRMT5 and the methylesterase PME-1, which removes the methyl group to promote holoenzyme disassembly. In AD brain tissue, reduced methylation of PP2A-C has been reported, which may contribute to impaired holoenzyme assembly and reduced tau dephosphorylation activity[@sontag2012].
Several endogenous inhibitor proteins specifically target PP2A and modulate its activity toward tau and other substrates. The protein CIP2A (cancerous inhibitor of PP2A) binds to and inhibits PP2A activity, and elevated CIP2A expression has been documented in AD brain tissue[@khanna2016]. SET, also known as I2PP2A (inhibitor 2 of PP2A), is another potent PP2A inhibitor that binds to the catalytic subunit and blocks its active site. SET is normally localized to the nucleus but can translocate to the cytoplasm under certain conditions, where it can inhibit PP2A-mediated dephosphorylation of cytoplasmic substrates including tau. The accumulation of SET in the cytoplasm of AD neurons has been proposed as a mechanism contributing to reduced PP2A activity and tau hyperphosphorylation.
Phosphorylation of PP2A-C at specific residues provides another layer of regulation over phosphatase activity. Phosphorylation at Tyr307 by Src family kinases inhibits PP2A activity, while phosphorylation at Thr304 by ATM or other kinases can also suppress catalytic function[@jun2020]. These phosphorylation events provide mechanisms for signal transduction pathways to modulate PP2A activity in response to cellular stimuli. In AD, increased phosphorylation of PP2A-C at inhibitory sites has been reported, contributing to reduced phosphatase activity and impaired tau dephosphorylation.
The expression and localization of specific PP2A regulatory subunits also contribute to regulation of tau dephosphorylation. The Bα regulatory subunit (PPP2R2A) is the predominant isoform in brain and is essential for targeting PP2A to tau[@liu2016]. Reduced expression of PPP2R2A has been observed in AD brain tissue, which may contribute to impaired tau dephosphorylation. Additionally, alternative splicing of PP2A regulatory subunit transcripts can generate isoforms with different substrate specificities, providing additional complexity in the regulation of PP2A function.
Alzheimer's disease is characterized by the accumulation of extracellular amyloid-beta plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau[@hardy2002]. The "tau hypothesis" of AD pathogenesis proposes that tau hyperphosphorylation and aggregation are central events in neurodegeneration, and that understanding the mechanisms regulating tau phosphorylation state is essential for developing effective therapies. PP2A plays a central role in this context, as reduced PP2A activity in AD brain tissue leads to impaired tau dephosphorylation and contributes to the formation of neurofibrillary tangles[@iqbal2009].
Multiple studies have documented reduced PP2A activity in AD brain tissue compared to age-matched controls. This reduction in activity has been observed in multiple brain regions affected by AD pathology, including the hippocampus and frontal cortex, and correlates with the severity of neurofibrillary pathology[@vogelsang2019]. The mechanisms underlying reduced PP2A activity in AD are multifactorial, involving changes in the expression and post-translational modification of PP2A subunits, increased association with inhibitory proteins, and altered holoenzyme composition. Together, these changes shift the balance toward tau hyperphosphorylation and contribute to the progression of tau pathology.
Several specific alterations in PP2A regulation have been identified in AD brain tissue. The expression of the PP2A Bα regulatory subunit (PPP2R2A) is reduced in AD brain, which may impair the targeting of PP2A to tau substrates[@chen2018]. Methylation of PP2A-C is also reduced, potentially due to altered activities of PRMT5 and PME-1, leading to impaired holoenzyme assembly. The levels of the PP2A inhibitor SET are elevated in AD brain tissue, and SET has been shown to colocalize with neurofibrillary tangles, suggesting a direct role in tau pathology[@scroggins2019]. Additionally, increased phosphorylation of PP2A-C at inhibitory tyrosine residues has been documented in AD.
The consequence of reduced PP2A activity in AD extends beyond tau hyperphosphorylation to include effects on multiple PP2A substrates that regulate neuronal function and survival. PP2A dephosphorylates multiple proteins involved in synaptic plasticity, cytoskeletal dynamics, and apoptotic pathways, and dysregulation of these functions may contribute to synaptic loss and neuronal death in AD[@liu2017]. This broader impact of PP2A dysregulation suggests that restoring PP2A activity could have beneficial effects beyond simply promoting tau dephosphorylation.
Animal models have provided important insights into the role of PP2A in tau pathology and support a causal relationship between reduced PP2A activity and tau hyperphosphorylation. Genetic reduction of PP2A activity in mice leads to tau hyperphosphorylation and aggregation, while pharmacological activation of PP2A can reduce tau pathology in models of AD[@liu2018]. These findings support the therapeutic potential of targeting PP2A in AD and other tauopathies.
The central role of PP2A in regulating tau phosphorylation makes it an attractive target for therapeutic intervention in AD and related tauopathies. Strategies aimed at restoring PP2A activity or removing barriers to its function could promote tau dephosphorylation and potentially halt or reverse the progression of neurofibrillary pathology[@vickers2015]. Several therapeutic approaches are being explored, including direct activation of PP2A, modulation of PP2A regulatory proteins, and restoration of normal PP2A post-translational modifications.
Direct activation of PP2A can be achieved using small molecule activators that bind to the phosphatase complex and enhance its catalytic activity. Several compounds have been identified that can activate PP2A, including the antibiotic nalidixic acid and its derivatives, as well as natural products such as curcumin and its analogs[@wu2020]. These compounds have shown efficacy in cellular and animal models of tauopathy, reducing tau phosphorylation and improving behavioral outcomes. However, the development of PP2A activators with suitable pharmacokinetic properties for clinical use remains a challenge.
Modulation of PP2A regulatory proteins represents an alternative therapeutic approach. Inhibition of PP2A inhibitors such as CIP2A or SET could restore PP2A activity and promote tau dephosphorylation[@lee2018]. Small molecule inhibitors of SET have been identified and tested in preclinical models, with some success in reducing tau pathology. Similarly, strategies to promote PP2A methylation by enhancing PRMT5 activity or inhibiting PME-1 could improve holoenzyme assembly and function. The feasibility of these approaches depends on the ability to develop selective inhibitors or activators of the relevant target proteins.
Another therapeutic strategy involves targeting the signaling pathways that lead to PP2A inhibition in AD. For example, inhibitors of the kinases that phosphorylate PP2A at inhibitory sites could prevent PP2A inactivation and maintain phosphatase activity. Similarly, modulation of upstream signaling pathways that regulate PP2A inhibitory proteins could indirectly enhance PP2A function.
Gene therapy approaches targeting PP2A subunits represent a more direct strategy for restoring PP2A function. Viral delivery of PP2A catalytic subunit or regulatory subunit genes to the brain could increase PP2A expression and activity. However, the complexity of PP2A regulation and the potential for unintended effects on other PP2A substrates make this approach challenging. Careful consideration must be given to achieving the right balance of PP2A activity in specific cellular compartments and neuronal populations.
The translation of PP2A-targeted therapies to clinical use will require careful attention to safety considerations, as global activation of PP2A could have unintended consequences on cellular functions beyond tau dephosphorylation. PP2A regulates numerous substrates involved in essential cellular processes, and excessive phosphatase activity could disrupt normal physiological functions. Strategies that specifically enhance PP2A activity toward tau, rather than globally activating the phosphatase, may be preferable.
Research on the PP2A-tau axis continues to advance our understanding of tauopathy pathogenesis and identify new therapeutic targets. Recent studies have employed proteomic and genomic approaches to identify novel PP2A-interacting proteins and regulatory mechanisms that influence tau dephosphorylation[@lau2020]. These studies have revealed unexpected complexity in PP2A regulation and identified new potential therapeutic targets within the PP2A regulatory network.
One area of active investigation concerns the specific PP2A holoenzyme compositions that are most effective for tau dephosphorylation. Different regulatory subunit isoforms show varying capacities for tau dephosphorylation, and identifying the optimal holoenzyme composition could lead to more targeted therapeutic approaches[@park2019]. Studies are also examining the role of post-translational modifications of tau in regulating its interaction with PP2A, as specific phosphorylation patterns may affect the efficiency of dephosphorylation.
Animal models continue to provide important insights into PP2A function in vivo. New genetic models that allow conditional and cell-type-specific manipulation of PP2A subunits are enabling more precise studies of PP2A function in neurons and glia[@zeng2018]. These models are also being used to test the efficacy of PP2A-targeted therapeutic approaches in vivo. Additionally, the development of induced pluripotent stem cell (iPSC) models from AD patients allows the study of PP2A dysregulation in human neurons and the testing of therapeutic compounds in disease-relevant cellular contexts.
Clinical research is beginning to explore the potential of PP2A-targeted approaches in human patients. Biomarker studies are examining whether measures of PP2A activity or its regulatory proteins can serve as indicators of disease progression or treatment response[@batsikos2019]. Additionally, clinical trials of compounds that target PP2A regulatory proteins are being planned or underway, representing the first steps toward translating basic science discoveries into clinical applications.
Emerging research is also exploring the role of PP2A in other tauopathies beyond AD, including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia with tau pathology (FTD-Tau)[@togo2002]. These diseases are characterized by distinct patterns of tau pathology and may involve different mechanisms of PP2A dysregulation. Understanding the disease-specific contributions of PP2A dysfunction could lead to personalized therapeutic approaches for different tauopathy subtypes.
Related Hypotheses: